A Leader’s Guide to Ethical 340B Program Management

The 340B drug pricing program has entered a new era of scrutiny, with pharmaceutical manufacturers, legislators, and safety-net providers all focused on program integrity. As covered entities navigate complex administrative dispute resolution processes and increasing oversight, maintaining ethical standards has never been more crucial for 340B program participants who dispense discounted drugs to eligible patients and provide comprehensive services.

Edward Vargas, founder of Virtue 340B, emphasizes this point:

“It’s always important to know when to say no. If it’s difficult for an independent, unbiased party to infer that your covered entity is maintaining responsibility of care and meeting the requirements of the 340B statute, then it probably shouldn’t be captured.”

Edward Vargas

Understanding Ethical Compliance in Today’s 340B Environment

For covered entities participating in the 340B program, ethical compliance goes beyond simply following the Public Health Service Act requirements. The Office of Pharmacy Affairs and HRSA expect covered entities to demonstrate good faith efforts in:

• Stretching scarce federal resources effectively
• Reaching more eligible patients and providing comprehensive services
• Maintaining transparency in how 340B savings support community health
• Ensuring proper documentation for all 340B drugs dispensed
• Following HRSA guidelines for contract pharmacy arrangements

Common Challenges for 340B Program Participants

Use of Program Savings

One of the primary ethical challenges covered entities face involves tracking and justifying the use of 340B savings. Vargas notes, “Many covered entities are not currently tracking their use of savings because it’s not a program requirement.” This creates a significant communication gap between frontline managers, program administrators, and finance departments, particularly in larger hospital systems.

Referral Claims Management

Another critical area involves the qualification of 340B prescriptions written by providers not directly employed or contracted by the organization. These “referral claims” occur when:

• A patient sees their primary care provider for a general exam
• The provider refers them to a specialist
• Prescriptions stem from the specialist visit
• The covered entity must determine 340B eligibility

The 340B statute requires three key pillars for patient eligibility:

1.     Active patient status

2.     Demonstrated provision of care

3.     Maintained responsibility and ongoing responsibility for care

Building an Ethical Framework for Your Covered Entity

Leadership’s Role in Program Integrity

“It’s a top-down approach,” Vargas emphasizes. “Really, it’s the leadership team that needs to set the standard for administering the program and how it will allocate the savings and account for it.” Without clear guidance from leadership, frontline workers may feel pressured to maximize revenue at the expense of compliance.

Key Components of an Ethical Framework

Establishing a robust ethical framework is crucial for long-term success for safety-net providers managing 340B program requirements. As Vargas emphasizes, covered entities must be able to demonstrate both quantitatively and qualitatively how they’re benefiting the community—beyond simply tracking the number of patients served. This means showing concrete improvements in patient outcomes and clearly illustrating how 340B savings help stretch scarce federal resources to expand access to care.

When pharmaceutical manufacturers and legislators scrutinize 340B covered entities and their contract pharmacy arrangements, a comprehensive ethical framework becomes your first defense. “If you can align your operations and the claims you’re capturing with those elements, you’re going to be best positioned to support the integrity of your program,” notes Vargas.

To build this foundation, covered entities must establish:

• Clear alignment with the 340B statute requirements
• Mechanisms for verifying responsibility of care
• Processes for monitoring 340B savings utilization
• Documentation systems for demonstrating community benefit
• Procedures for handling administrative dispute resolution

These components help ensure compliance with the Public Health Service Act while providing a structure for addressing potential administrative dispute resolution needs before they escalate to the ADR process.

Best Practices for 340B Compliance and Oversight

When managing covered outpatient drugs through the 340B program, strong compliance practices serve as your frontline defense against potential disputes. Covered entities and manufacturers should carefully evaluate their processes to prevent issues before they escalate to the 340B administrative dispute resolution process. When hospitals participating in the 340B program are overcharged for covered outpatient drugs or manufacturers question whether covered entities have violated the prohibitions against diversion, both parties must navigate a complex web of requirements.

Through the OPA director and designee, the Department of Health and Human Services has established clear guidelines for how covered entities may proceed with claims related to drug pricing. Organizations should implement robust compliance practices before a claim is deemed complete or parties and HRSA become involved in an ADR panel assignment. These best practices help ensure that information systems and documentation properly support the purchase of outpatient drugs at the correct 340B ceiling price.

Let’s explore the essential components of an effective compliance program…

Staff Training and Empowerment

Frontline 340B managers serve as gatekeepers for program integrity. Organizations should:

• Provide comprehensive training on ethical standards
• Empower staff to make conservative decisions
• Supply clear examples of eligible and ineligible claims
• Maintain open communication channels across departments

Regular Audit Procedures

To ensure adherence to ethical standards, covered entities should conduct regular audits focusing on:

• Referral captured claims
• Mixed-eligibility clinical environments
• Documentation substantiation
• Contract pharmacy arrangements
• Potential diversion or duplicate discounts

Demonstrating Community Benefit

At Virtue 340B, we strongly advocate for quantitative and qualitative community impact measurement. Covered entities should track:

• Enhanced patient outcomes
• Expanded access to care
• Comprehensive services provided
• Use of 340B savings to support community programs

Documentation Requirements

To support compliance during a HRSA audit or manufacturer audit, maintain thorough records of:

• Provider documentation in progress notes
• Care coordination efforts
• Patient eligibility verification
• Outpatient drugs purchased through the program

Future Considerations for 340B Program Management

Significant changes are reshaping how covered entities manage their 340B drug pricing program administrative responsibilities. Let’s point to a telling example from recent industry developments: pharmaceutical manufacturers are pushing to implement a rebate model requiring hospitals and health centers to purchase outpatient drugs at retail cost upfront. Under this model, manufacturers would review claims by covered entities after the fact to determine 340B eligibility before issuing rebates. This shift could create substantial cash flow challenges for safety-net providers, particularly when managing Medicare Part B and Medicaid claims.

Beyond the rebate model, manufacturers are increasing their scrutiny of contract pharmacy arrangements, with some advocating for restricted clinical environments where 340B drugs can be dispensed. “Last year’s reports showed unprecedented lobbying dollars being spent by big pharma related to the 340B program,” Vargas notes, explaining how these efforts drive enhanced reporting requirements and expanded manufacturer audit rights. To maintain program integrity, covered entities must carefully evaluate how these changes impact their ability to stretch scarce federal resources and continue providing comprehensive services to their communities.

Conclusion

Ethical management of your 340B program requires constant vigilance and commitment from all levels of the organization. As Vargas concludes, “Aligning your practices with the intent of the program and the core requirements of the 340B statute will best position you to support the integrity of your program while continuing to stretch scarce federal resources as far as possible.”

Covered entities must balance program benefits with compliance risks while focusing on their core mission: reaching more eligible patients and providing more comprehensive services to their communities. Through careful attention to ethical guidelines and robust oversight procedures, organizations can ensure their 340B program continues to serve its intended purpose while meeting all regulatory requirements.